{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:02:03Z","timestamp":1778605323293,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00277-022-04776-0","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T14:03:12Z","timestamp":1650549792000},"page":"1217-1226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma"],"prefix":"10.1007","volume":"101","author":[{"given":"Tan-Huy","family":"Chu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeung-Chul","family":"Mun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Mee","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Sup","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"issue":"1","key":"4776_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"4776_CR2","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538-548","journal-title":"Lancet Oncol"},{"issue":"11","key":"4776_CR3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364(11):1046\u20131060","journal-title":"N Engl J Med"},{"issue":"1","key":"4776_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3324\/haematol.2019.219295","volume":"105","author":"M Beksac","year":"2020","unstructured":"Beksac M, Seval GC, Kanellias N, Coriu D, Rosinol L, Ozet G, Goranova-Marinova V, Unal A, Bila J, Ozsan H et al (2020) A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica 105(1):201\u2013208","journal-title":"Haematologica"},{"issue":"11","key":"4776_CR5","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3324\/haematol.2012.078519","volume":"97","author":"J Blade","year":"2012","unstructured":"Blade J, de Larrea CF, Rosinol L (2012) Extramedullary involvement in multiple myeloma. Haematologica 97(11):1618\u20131619","journal-title":"Haematologica"},{"issue":"8","key":"4776_CR6","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood-2015-07-635383","volume":"127","author":"C Touzeau","year":"2016","unstructured":"Touzeau C, Moreau P (2016) How I treat extramedullary myeloma. Blood 127(8):971\u2013976","journal-title":"Blood"},{"issue":"3","key":"4776_CR7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.17338","volume":"194","author":"L Rosinol","year":"2021","unstructured":"Rosinol L, Beksac M, Zamagni E, Van de Donk N, Anderson KC, Badros A, Caers J, Cavo M, Dimopoulos MA, Dispenzieri A et al (2021) Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol 194(3):496\u2013507","journal-title":"Br J Haematol"},{"issue":"2","key":"4776_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1046\/j.1365-2141.2002.03258.x","volume":"116","author":"IM Dahl","year":"2002","unstructured":"Dahl IM, Rasmussen T, Kauric G, Husebekk A (2002) Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol 116(2):273\u2013277","journal-title":"Br J Haematol"},{"issue":"4","key":"4776_CR9","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.celrep.2015.06.059","volume":"12","author":"AM Roccaro","year":"2015","unstructured":"Roccaro AM, Mishima Y, Sacco A, Moschetta M, Tai YT, Shi J, Zhang Y, Reagan MR, Huynh D, Kawano Y et al (2015) CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation. Cell Rep 12(4):622\u2013635","journal-title":"Cell Rep"},{"issue":"1","key":"4776_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","volume":"34","author":"M Bhutani","year":"2020","unstructured":"Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ (2020) Extramedullary multiple myeloma. Leukemia 34(1):1\u201320","journal-title":"Leukemia"},{"issue":"28","key":"4776_CR11","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","volume":"29","author":"J Blade","year":"2011","unstructured":"Blade J, de Fernandez Larrea C, Rosinol L, Cibeira MT, Jimenez R (2011) Powles R Soft-tissue plasmacytomas in multiple myeloma incidence mechanisms of extramedullary spread and treatment approach. J Clin Oncol 29(28):3805\u20133812","journal-title":"J Clin Oncol"},{"issue":"2","key":"4776_CR12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2013.094409","volume":"99","author":"L Pour","year":"2014","unstructured":"Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, Sandecka V, Adam Z, Krejci M, Kuglik P et al (2014) Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica 99(2):360\u2013364","journal-title":"Haematologica"},{"issue":"11","key":"4776_CR13","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","volume":"97","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, Alsayed Y, Waheed S, Haider S, Restrepo A et al (2012) Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica 97(11):1761\u20131767","journal-title":"Haematologica"},{"issue":"6","key":"4776_CR14","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/leu.2011.29","volume":"25","author":"KD Short","year":"2011","unstructured":"Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A, Gertz M, Kumar S, Mikhael J, Roy V et al (2011) Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 25(6):906\u2013908","journal-title":"Leukemia"},{"issue":"26","key":"4776_CR15","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T et al (2015) Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 33(26):2863\u20132869","journal-title":"J Clin Oncol"},{"issue":"6","key":"4776_CR16","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, Dozza L, van der Holt B, Zweegman S, Oliva S et al (2020) Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol 7(6):e456\u2013e468","journal-title":"Lancet Haematol"},{"issue":"3","key":"4776_CR17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00277-014-2216-8","volume":"94","author":"SE Lee","year":"2015","unstructured":"Lee SE, Kim JH, Jeon YW, Yoon JH, Shin SH, Eom KS, Kim YJ, Kim HJ, Lee S, Cho SG et al (2015) Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma. Ann Hematol 94(3):445\u2013452","journal-title":"Ann Hematol"},{"issue":"1","key":"4776_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.2019.219139","volume":"105","author":"V Montefusco","year":"2020","unstructured":"Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, Musolino C, Patriarca F, Musto P, Galieni P et al (2020) Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. Haematologica 105(1):193\u2013200","journal-title":"Haematologica"},{"issue":"2","key":"4776_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/bmt.2013.150","volume":"49","author":"C de Fernandez Larrea","year":"2014","unstructured":"de Fernandez Larrea C, Jimenez R, Rosinol L, Gine E, Tovar N, Cibeira MT, Fernandez-Aviles F, Martinez C, Rovira M, Blade J (2014) Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma. Bone Marrow Transplant 49(2):223\u2013227","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"4776_CR20","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/bmt.2017.165","volume":"52","author":"L Kumar","year":"2017","unstructured":"Kumar L, Gogi R, Patel AK, Mookerjee A, Sahoo RK, Malik PS, Sharma A, Thulkar S, Kumar R, Biswas A et al (2017) Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome. Bone Marrow Transplant 52(10):1473\u20131475","journal-title":"Bone Marrow Transplant"},{"issue":"10214","key":"4776_CR21","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA et al (2019) Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 394(10214):2096\u20132107","journal-title":"Lancet"},{"issue":"8","key":"4776_CR22","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV et al (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375(8):754\u2013766","journal-title":"N Engl J Med"},{"issue":"14","key":"4776_CR23","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K et al (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375(14):1319\u20131331","journal-title":"N Engl J Med"},{"key":"4776_CR24","doi-asserted-by":"crossref","unstructured":"Jelinek T, Sevcikova T, Zihala D, Popkova T, Kapustova V, Broskevicova L, Capkova L, Rihova L, Bezdekova R, Sevcikova S et al (2021) Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia 36(1):288\u2013291","DOI":"10.1038\/s41375-021-01343-w"},{"issue":"18","key":"4776_CR25","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A et al (2019) Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 380(18):1726\u20131737","journal-title":"N Engl J Med"},{"issue":"10","key":"4776_CR26","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","volume":"6","author":"Z Yan","year":"2019","unstructured":"Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y, Shi M, Lan J, Fei X, Jin L et al (2019) A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol 6(10):e521\u2013e529","journal-title":"Lancet Haematol"},{"key":"4776_CR27","doi-asserted-by":"crossref","unstructured":"Thangaraj JL, Ahn SY, Jung SH, Vo MC, Chu TH, Thi Phan MT, Kwon M, Lee KH, Kim M, Song GY et al (2021) Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model. Cell Mol Immunol\u00a018(7):1652\u20131661","DOI":"10.1038\/s41423-021-00686-9"},{"key":"4776_CR28","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.3389\/fimmu.2018.01798","volume":"9","author":"MC Vo","year":"2018","unstructured":"Vo MC, Yang S, Jung SH, Chu TH, Lee HJ, Lakshmi TJ, Park HS, Kim HJ, Lee JJ (2018) Synergistic antimyeloma activity of dendritic cells and pomalidomide in a murine myeloma model. Front Immunol 9:1798","journal-title":"Front Immunol"},{"key":"4776_CR29","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.3389\/fimmu.2018.01370","volume":"9","author":"MC Vo","year":"2018","unstructured":"Vo MC, Jung SH, Chu TH, Lee HJ, Lakshmi TJ, Park HS, Kim HJ, Rhee JH, Lee JJ (2018) Lenalidomide and programmed death-1 blockade synergistically enhances the effects of dendritic cell vaccination in a model of murine myeloma. Front Immunol 9:1370","journal-title":"Front Immunol"},{"key":"4776_CR30","doi-asserted-by":"crossref","unstructured":"Chu TH, Vo MC, Park HS, Lakshmi TJ, Jung SH, Kim HJ, Lee JJ (2021) Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma. Cancer Immunol Immunother 70(1):31\u201345","DOI":"10.1007\/s00262-020-02654-0"}],"updated-by":[{"DOI":"10.1007\/s00277-022-04854-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000}}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04776-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04776-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04776-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T09:11:27Z","timestamp":1653297087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04776-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["4776"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04776-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]},"assertion":[{"value":"27 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00277-022-04854-3","URL":"https:\/\/doi.org\/10.1007\/s00277-022-04854-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the institutional ethics committee of each participating institution and conducted in accordance with the Declaration of Helsinki. The committee waived the need for informed patient consent because of the retrospective nature of the work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}